Dr. Natalie Martinez presented on tarlatumab, a bispecific T cell engager targeting DLL3 in small cell lung cancer (SCLC), which received FDA accelerated approval after showing promising results in phase 2 trials, including a 40% tumor reduction and 14.3-month median survival. Ongoing studies are exploring its use in earlier-stage disease, with manageable side effects like CRS and neurologic events. Presented at 2025 SPS Puerto Rico.